Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
- Otsuka, Lundbeck Initiate Multinational PIII Program of Novel AD Treatment Lu AE58054
October 15, 2013
- Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
- PAREXEL CEO Says Japan Will Remain as Important Market for CROs, Hopes Outsourcing Increases in Japan
October 11, 2013
- Ono to Set Up Local Subsidiary in South Korea, Eyeing Commercialization of Own Brands
October 11, 2013
- 36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
October 11, 2013
- 36 Drug Makers Spent 120 Billion Yen on Information Provision; Foreign-affiliated Companies Top Spending List
October 11, 2013
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
- Kaketsuken Submits 1st Japan-Made Hemophilia Inhibitor Treatment for Approval
October 9, 2013
- Takeda’s Norovirus Vaccine Misses Primary Endpoint in PI/II, but Reduces Vomiting, Diarrhea
October 9, 2013
- Chugai Files NDA for ALK Inhibitor Alectinib in Japan for NSCLC
October 9, 2013
- Onychomycosis Treatment Efinaconazole Licensed from Kaken Approved in Canada
October 9, 2013
- Astellas, US Biotech Venture to Collaborate on Mitochondrial Disease Therapies
October 8, 2013
- Quintiles Aims to Expand Business in Japan with More Employees: CEO
October 8, 2013
- Ethical Drug Sales Up 0.7% in August: Crecon Report
October 8, 2013
- 3 Combination Drugs for Asthma, COPD Get Approval to Fuel Competition; NHI Price Listing Expected in November
October 7, 2013
- Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated
October 7, 2013
- Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
October 7, 2013
- Novartis Japan Execs Face 30% Pay Cut amid Diovan Scandal, Compliance Advisory Board to Be Set Up
October 4, 2013
- Mundipharma Initiates Clinical Study of PTCL Treatment Pralatrexate in Japan
October 4, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…